chimeric antigen-receptor

Oncology

CAR-NK cell therapies are frequently misunderstood, despite growing clinical and preclinical data supporting their potential.

News

Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.